Chimeric antigen receptor T-cells: Properties, production, and quality control

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is a groundbreaking adoptive immunotherapy for hematological malignancies.
• CAR T-cell therapy has demonstrated significant success in treating B-cell lineage lymphoid malignancies since its clinical introduction in 2017.

Purpose of the Study:

• To review the molecular design, mechanisms of action, and production methods of CAR T-cell therapies.
• To discuss the clinical applications and evaluation technologies for CAR T-cell therapies.
• To highlight the importance of standardization, quality control, and monitoring for CAR T-cell therapy safety and efficacy.

Main Methods:

• Genetic engineering of autologous T-cells ex vivo to express chimeric antigen receptors (CARs).
• CARs comprise an extracellular antigen-binding domain and intracellular co-stimulatory signaling domains for T-cell activation and persistence.
• Utilizing CAR T-cells to harness the patient's immune system to target and eliminate tumor cells.

Main Results:

• CAR T-cells overcome tumor immune evasion mechanisms, generating potent anti-tumor responses.
• CAR T-cell therapy shows remarkable therapeutic outcomes in lymphoid malignancies.
• The intracellular co-stimulatory domains (e.g., CD137) are crucial for CAR T-cell proliferation, survival, and durable efficacy.

Conclusions:

• CAR T-cell therapy represents a significant advancement in treating hematological cancers.
• Standardization, quality control, and monitoring are essential for ensuring the safety and efficacy of CAR T-cell therapies.
• Ongoing research and technological advancements continue to refine CAR T-cell evaluation and application.